RayKnowChina Research Map
Shortlist0

Guangdong Medical University

广东医科大学

ZhanjiangUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.9%Leads under 1 in 100 of China's research papers on NPC

Led 21 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
2
Research papers it led
21
Trials it led
3
Share of China's trials
0.5%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025
ThemesInduction / concurrent chemotherapyRadiotherapy techniqueRecurrent / metastatic disease

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University18

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A case of diabetic ketoacidosis triggered by immune checkpoint inhibitors in the treatment of recurrent nasopharyngeal carcinoma.2025Anti-cancer drugs
  2. Proton pump inhibitors may increase the risk of cisplatin-induced acute kidney injury in patients with nasopharyngeal carcinoma: a prospective cohort study.2024Scientific reportsFree full text
  3. Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma.2024Cancer medicineFree full text
  4. Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.2023MedicineFree full text
  5. Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study.2023MedicineFree full text
Trials on ClinicalTrials.gov6
  1. Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07136519Lead sponsorPhase 2Start 2025-07
  2. Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal CarcinomaRecruitingNCT07327216Lead sponsorPhase 3Start 2022-08
  3. Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07362979Study sitePhase 2Start 2026-03
  4. Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal CavityNot yet recruitingNCT07072000Study sitePhase 3Start 2025-08
  5. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  6. Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal CarcinomaCompletedNCT07920250Lead sponsorPhase 2Start 2024-11

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.2%Leads under 1 in 100 of China's research papers on ESCC

Led 5 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 222025
ThemesMolecular markers & genomicsImaging & AISurgery

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University3
  2. Affiliated Gaozhou People's Hospital of Guangdong Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.3%Leads under 1 in 100 of China's research papers on HCC

Led 40 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
40
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University21
  2. First Dongguan Affiliated Hospital3
  3. Huizhou Central People's Hospital Counted in the group total2
  4. Affiliated Dongguan Songshan Lake Central Hospital of Guangdong Medical University1
  5. Shenzhen Longhua District Central Hospital Counted in the group total1
  6. Children's Medical Center Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.1%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 14 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025
ThemesImaging & AIPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University Counted in the group total9
  2. Central People's Hospital, Guangdong Medical University1
  3. Affiliated Dongguan Songshan Lake Central Hospital of Guangdong Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.4%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 8 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University7
  2. Guangdong Medical University Affiliated Second Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.2%Leads under 1 in 100 of China's research papers on Myeloma

Led 4 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025
ThemesRelapse & resistanceDrug combinationsDiagnosis, MRD & risk

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
0
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov1
  1. JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ LeukemiaRecruitingNCT06940960Lead sponsorN/AStart 2025-05

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH New since 2021

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025
ThemesTreatment regimensEBV & infection triggersLymphoma & cancer-related HLH

Hospitals counted here

  1. Shunde Women and Children's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.1%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 1.0%

Led 1 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.03%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.3%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 2 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Guangdong Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov